Table 3. Progression-free survival and response by time to relapse in ASPIRE and ENDEAVOR.

	ASPIRE (1R1T subgroup)				ENDEAVOR (1R1T subgroup)
	Early relapsers		Late relapsers		Early relapsers		Late relapsers
	KRd (n=19)	Rd (n=19)	KRd (n=69)	Rd (n=59)	Kd (n=23)	Vd (n=28)	Kd (n=99)	Vd (n=110)
PFS
Median PFS, months (95% CI)	15.2 (5.1–24.1)	9.3 (3.9–16.1)	33.5 (25.9–38.9)	24.3 (15.0–NE)	NE (7.1–NE)	8.0 (2.8–12.1)	NE (15.6–NE)	11.2 (8.8–NE)
HR, KRd/Rd or Kd/Vd (95% CI)	0.751 (0.353–1.599)		0.718 (0.432–1.195)		0.357 (0.153–0.832)		0.479 (0.297–0.771)
P-value (one-sided)	0.2279		0.0996		0.0065		0.0010
Overall response
CR or better, n (%)	1 (5.3)	0	27 (39.1)	8 (13.6)	0	0	18 (18.2)	13 (11.8)
VGPR or better, n (%)	13 (68.4)	7 (36.8)	56 (81.2)	30 (50.8)	12 (52.2)	5 (17.9)	63 (63.6)	45 (40.9)
ORR (95% CI)	78.9 (54.4–93.9)	57.9 (33.5–79.7)	92.8 (83.9–97.6)	72.9 (59.7–83.6)	87.0 (66.4–97.2)	50.0 (30.6–69.4)	82.8 (73.9–89.7)	71.8 (62.4–80.0)

Abbreviations: 1R1T, first relapse after frontline ASCT; ASCT, autologous stem cell transplantation; CI, confidence interval; CR, complete response; HR, hazard ratio; Kd, carfilzomib+dexamethasone; KRd, carfilzomib+lenalidomide+dexamethasone; NE, not estimable; ORR, overall response rate; PFS, progression-free survival; Rd, lenalidomide+dexamethasone; Vd, bortezomib+dexamethasone; VGPR, very good partial response. Includes patients who enrolled in study at first relapse post-ASCT. Early relapsers refers to patients relapsing <12 months post-ASCT. Late relapsers refers to patients relapsing ⩾12 months post-ASCT.